[{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ SAB Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ SAB Biotherapeutics"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Human Rho D Immune Globulin","moa":"IgG","graph1":"Dermatology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL","sponsor":"University of Queensland","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Squalene API","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ University of Queensland","highestDevelopmentStatusID":"4","companyTruncated":"CSL \/ University of Queensland"},{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"SAB-185","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Immunoglobulin G 285-292","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Chemokine-derived antifibrotic peptides","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Angion Biomedica","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Angion Biomedica","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"6","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Stem cell gene therapy","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL","sponsor":"Vitaeris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Clazakizumab","moa":"IL-6","graph1":"Immunology","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Albutrepenonacog Alfa","moa":"Factor X","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Human C1 Esterase Inhibitor","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Hyperimmune immunoglobulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ National Institutes of Health"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Commonwealth of Australia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"V451","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ Commonwealth of Australia","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Commonwealth of Australia"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved","graph3":"CSL Vifor","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.14999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"MF59-adjuvanted trivalent influenza vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"oral","sponsorNew":"CSL Vifor \/ ChemoCentryx","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ ChemoCentryx"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Apolipoprotein A-I [human]","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Angion Biomedica","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ANG-3777","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"CSL Vifor","amount2":0.34000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Apolipoprotein A-I [human]","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Fresenius Kabi"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Influenza A (H5N1) monovalent vaccine, adjuvanted","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"CSL","sponsor":"CSL","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"v451","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"6","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL Vifor \/ ChemoCentryx","highestDevelopmentStatusID":"8","companyTruncated":"CSL Vifor \/ ChemoCentryx"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Chewable Tablet","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"MF59-adjuvanted trivalent influenza vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":2.0499999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"Intravenous infusion","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"OPKO Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Termination","leadProduct":"Calcifediol","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL Vifor \/ Vifor","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Vifor"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent influenza vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Seqirus"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Travere Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0.19,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.19,"dosageForm":"Tablet","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Cell-based Quadrivalent Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Angion Biomedica","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Terevalefim","moa":"HGF","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Behring","sponsor":"HCmed Innovations","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Human Plasma-derived Polyvalent Immunoglobulin G","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"CSL Behring \/ HCmed Innovations","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ HCmed Innovations"},{"orgOrder":0,"company":"CSL","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL","amount2":11.699999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":11.699999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Angion Biomedica","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vamifeport","moa":"Ferroportin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","graph1":"Immunology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"Seqirus","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Influenza A (H5N1) Monovalent Vaccine, Adjuvanted","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Cara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Cara Therapeutics"},{"orgOrder":0,"company":"Seqirus","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Seqirus"},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","graph1":"Immunology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL Vifor \/ ChemoCentryx","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ ChemoCentryx"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSL Vifor \/ Cara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Cara Therapeutics"},{"orgOrder":0,"company":"CSL","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Dual endothelin\/Angiotensin receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSL \/ Travere Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Travere Therapeutics"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lyophilized Human C1-esterase","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"H5N8 A\/Astrakhan Virus Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seqirus","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Seqirus \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Seqirus \/ BARDA"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"sa-mRNA Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"CSL","sponsor":"Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ Translational Sciences","highestDevelopmentStatusID":"6","companyTruncated":"CSL \/ Translational Sciences"},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"ARCT-154","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CSL","amount2":4.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":4.5,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not Applicable"},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Orsini Specialty Pharmacy","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Orsini Specialty Pharmacy"},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avacopan","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Amarin","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Seqirus"},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Garadacimab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avacopan","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Immune Globulin G","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ Cara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Cara Therapeutics"},{"orgOrder":0,"company":"CSL","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL","amount2":11.699999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":11.699999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":2.0499999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"H5N8 A\/Astrakhan Virus Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"CSL \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ BARDA"},{"orgOrder":0,"company":"CSL","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ARCT-154","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"2","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"CSL","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ARCT-154","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Garadacimab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Not Applicable"},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"Seqirus","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Seqirus"},{"orgOrder":0,"company":"CSL","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Self-amplifying mRNA Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Zeria Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Safinamide Mesylate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Pharmanovia"},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Garadacimab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"hFIX Padua gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Suspension for Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"FXIIa","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Self-amplifying mRNA Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CSL \/ Arcturus Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"FXIIa","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by CSL
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
